摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-3,3,3-trifluoro-2-methylpropane-1,2-diamine | 911424-53-8

中文名称
——
中文别名
——
英文名称
(S)-3,3,3-trifluoro-2-methylpropane-1,2-diamine
英文别名
(2S)-3,3,3-Trifluoro-2-methylpropane-1,2-diamine
(S)-3,3,3-trifluoro-2-methylpropane-1,2-diamine化学式
CAS
911424-53-8
化学式
C4H9F3N2
mdl
——
分子量
142.124
InChiKey
UCGCJYITRNQIKW-VKHMYHEASA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.3
  • 重原子数:
    9
  • 可旋转键数:
    1
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    52
  • 氢给体数:
    2
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    描述:
    (S)-3,3,3-trifluoro-2-methylpropane-1,2-diamine溴化氰 为溶剂, 生成 (S)-4-methyl-4-trifluoromethyl-4,5-dihydro-1H-imidazol-2-ylamine hydrobromide
    参考文献:
    名称:
    NOVEL 2,3-DIHYDRO-1H-IMIDAZO(1,2-A)PYRIMIDIN-5-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF
    摘要:
    本发明涉及式(I)的新材料,其中R1是可选取的取代L-芳基或杂芳基,其中L是:烷基或CO,或LX,其中L是烷基,X是O或S;R2是氢或烷基;R3是可选取的Hal取代的烷基;R4是H或Hal,其中所述材料以任何异构体形式及其盐的形式用作药物。
    公开号:
    US20120142679A1
  • 作为产物:
    描述:
    (2R)-2-((S)-1-aminomethyl-2,2,2-trifluoro-1-methylethylamino)-2-phenylethanol甲烷磺酸 、 palladium hydroxide, 20 wt% on carbon 、 氢气 作用下, 以 甲醇 为溶剂, 25.0 ℃ 、500.01 kPa 条件下, 反应 24.0h, 以4.50 g的产率得到(S)-3,3,3-trifluoro-2-methylpropane-1,2-diamine
    参考文献:
    名称:
    Pyrimidinone Derivatives as Antimalarial Agents
    摘要:
    这项发明涉及一种新型的嘧啶酮基杂环化合物,这些化合物是寄生虫生长抑制剂,其一般式为(I),其中Y是从三种桥联吗啉中选择的吗啉,L是键或连接物,n=0或1,当n=0时R2是甲基基团,当n=1时是氢原子。其制备方法和治疗用途。
    公开号:
    US20150183804A1
点击查看最新优质反应信息

文献信息

  • PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF
    申请人:Arigon Jerome
    公开号:US20130289031A1
    公开(公告)日:2013-10-31
    The invention relates to novel products of formula (Ia) or (Ib): these products being in all the isomeric forms and salts as drugs, notably as anticancer drugs.
    这项发明涉及公式(Ia)或(Ib)的新产品:这些产品以所有同分异构体和盐的形式作为药物,特别是作为抗癌药物。
  • NOVEL 2,3-DIHYDRO-1H-IMIDAZO(1,2-A)PYRIMIDIN-5-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF
    申请人:Brolio Maurice
    公开号:US20120142679A1
    公开(公告)日:2012-06-07
    The invention relates to the novel materials of formula (I), where R 1 is an optionally substituted L-aryl or -heteroaryl, such that L is: an alkyl or CO, or L X, with L being an alkyl and X being O or S; R 2 is H or an alkyl; R 3 is an alkyl optionally substituted by Hal; and R 4 is Hou Hal, wherein said materials are in any isomeric form and the salts thereof, to be used as drugs.
    本发明涉及式(I)的新材料,其中R1是可选取的取代L-芳基或杂芳基,其中L是:烷基或CO,或LX,其中L是烷基,X是O或S;R2是氢或烷基;R3是可选取的Hal取代的烷基;R4是H或Hal,其中所述材料以任何异构体形式及其盐的形式用作药物。
  • Novel 2,3-Dihydro-1H-imidazopyrimidin-5-one and this 1,2,3,4-tetrahydropyrimidopyrimidin-6-one Derivatives Comprising a Substituted Morpholine, Preparation Thereof and Pharmaceutical Use Thereof
    申请人:SANOFI
    公开号:US20150148328A1
    公开(公告)日:2015-05-28
    The invention relates to the novel products of formula (I) with p, q=0, 1 or 2; R1=phenyl, pyridyl; —(CH 2 ) m —Ra; alkylene; cycloalkyl; heterocycloalkyl; alkyl; —SO 2 —Rb; —CO—Re; m=1 or 2; Ra=aryl, heteroaryl, —CO-cycloalkyl, —CO-heterocycloalkyl, —CO—Rb, —C(Rb)═N—ORc, —CO 2 Rd, —CONRxRy; Rb=alkyl, aryl, heteroaryl; Rc=H, alkyl; Rd=alkyl, cycloalkyl; Re=alkyl, cycloalkyl, aryl, heteroaryl; NRxRy with Rx,Ry=H, alkyl, cycloalkyl, alkoxy, phenyl, or form with N a ring with optionally O, N; R2, R3=H, alkyl, CF 3, or form with C a ring with optionally O, S and N; R4=H, F, Cl, CH 3 or CN; the morpholine is substituted with Me, and optionally substituted with F, OH; or is (Formula 1a) and the isomer of configuration R,R (Formula 1b) these products being in all the isomer forms and the salts, as medicaments, in particular as anticancer medicaments.
    本发明涉及公式(I)的新型产物,其中p,q = 0、1或2;R1 = 苯基、吡啶基;—(CH2)m—Ra;烷基;环烷基;杂环烷基;烷基;—SO2—Rb;—CO—Re;m = 1或2;Ra = 芳基、杂芳基、—CO-环烷基、—CO-杂环烷基、—CO—Rb、—C(Rb)═N—ORc、—CO2Rd、—CONRxRy;Rb = 烷基、芳基、杂芳基;Rc = H、烷基;Rd = 烷基、环烷基;Re = 烷基、环烷基、芳基、杂芳基;NRxRy,其中Rx,Ry = H、烷基、环烷基、烷氧基、苯基,或与N形成一个环,该环可以选择性地含有O、N;R2,R3 = H、烷基、CF3,或与C形成一个环,该环可以选择性地含有O、S和N;R4 = H、F、Cl、CH3或CN;吗啡环以Me取代,或以F、OH取代;或为(公式1a),具有R,R构型的异构体(公式1b)。这些产物以所有的异构体形式和盐形式作为药物,特别是作为抗癌药物。
  • Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof
    申请人:Arigon Jerome
    公开号:US08815853B2
    公开(公告)日:2014-08-26
    The invention relates to novel products of formula (Ia) or (Ib): these products being in all the isomeric forms and salts as drugs, notably as anticancer drugs.
    本发明涉及公式(Ia)或(Ib)的新型产物:这些产物以所有同分异构体和盐的形式作为药物,特别是作为抗癌药物。
  • Pyrimidinone derivatives as antimalarial agents
    申请人:SANOFI
    公开号:US09321790B2
    公开(公告)日:2016-04-26
    The invention relates to novel pyrimidinone-based heterocyclic compounds which are parasite growth inhibitors, having the general formula (I) in which Y is a morpholine chosen from three bridged morpholines, L is a bond or a linker, n=0 or 1 and R2 is a methyl group when n=0 and a hydrogen atom when n=1. Process for the preparation thereof and therapeutic use thereof.
    本发明涉及一种新型嘧啶酮类杂环化合物,其为寄生虫生长抑制剂,具有一般式(I),其中Y为三种桥式吗啡啶中的一种,L为化学键或连接剂,n=0或1,当n=0时,R2为甲基基团,当n=1时,R2为氢原子。本发明还涉及其制备方法和治疗用途。
查看更多